Other Science

FDA Clears Promega OncoMate™ MSI Dx Analysis System

Wednesday, July 28, 2021 - 6:00pm

The OncoMate MSI Dx Analysis System (OncoMate MSI), developed by Promega , has been cleared by the US Food and Drug Administration (FDA) as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.

Key Points: 
  • The OncoMate MSI Dx Analysis System (OncoMate MSI), developed by Promega , has been cleared by the US Food and Drug Administration (FDA) as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.
  • View the full release here: https://www.businesswire.com/news/home/20210728005823/en/
    The OncoMate MSI Dx Analysis System developed by Promega has been cleared by the US Food and Drug Administration (FDA) as an in vitro diagnostic medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors.
  • Promega also intends to seek regulatory clearance for a Promega MSI IVD in China where the Promega MSI technology received innovation status and priority review by the National Medical Products Administration (NMPA).
  • To learn more about the OncoMate MSI Dx Analysis System, visit: www.promega.com/OncoMateIVD
    Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry.

Stilla Launches Access Program for Industry’s First Six-Color Digital PCR System

Wednesday, July 28, 2021 - 5:26pm

Stilla Technologies , the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industrys first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today.

Key Points: 
  • Stilla Technologies , the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industrys first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today.
  • This represents a broad portfolio expansion of the Companys original three-color naica system and includes reagents and digital PCR consumables, automated analytical instrumentation, and turnkey visualization software.
  • Stilla is offering scientists an opportunity to experience the power and flexibility of 6-color Digital PCR by providing a range of options to drive their evaluations, including both hands-on or remote demonstrations of the naica system.
  • For more information on the Crystal Digital PCR Access Program, email demo@stillatechnologies.com or sign up online at: https://www.stillatechnologies.com/6-color-dpcr/ .

Japan’s Kewpie Corporation, Pioneer of the Hyaluronic Acid Revolution, Has Just Revealed Its Mechanism

Wednesday, July 28, 2021 - 6:00pm

Now Kewpie Corporation has forged new ground by releasing heretofore unknown evidence of how that works.

Key Points: 
  • Now Kewpie Corporation has forged new ground by releasing heretofore unknown evidence of how that works.
  • In June of this year Kewpie addressed that same ISHAS conference, and it once again changed the game.
  • As hyaluronan activates the collagenic cycle beneath the corneal layer of the skin, its loss disrupts the skins ability to maintain moisture.
  • This responsibility is central to Kewpie Corporations credo, and it makes Hyabest(S)LF-P, its producer and culture singular in the field.

University Hospitals, Cleveland and Edgility to Expand Collaboration on the Hospital@Home Platform

Wednesday, July 28, 2021 - 4:57pm

Edgility, Inc. will provide the technology platform to orchestrate University Hospitals (UH)s Hospital-at-Home offering.

Key Points: 
  • Edgility, Inc. will provide the technology platform to orchestrate University Hospitals (UH)s Hospital-at-Home offering.
  • Edgility, specializing in orchestrating complex healthcare workflows, will provide the technology to orchestrate UH's H@H operations.
  • "Edgility is proud of this collaboration with UH to be country's first Hospital-at-Home platform," according to Lisa Meyer, MSN, RN, NE-BC, Edgility's Chief Outcomes Officer.
  • The systems flagship quaternary care, academic medical center, University Hospitals Cleveland Medical Center, is affiliated with Case Western Reserve University School of Medicine, Oxford University and the Technion Israel Institute of Technology.

Eurofins Abraxis Announces the World’s First Rapid Glyphosate Method to Achieve AOAC Performance Test MethodSM Certification Status

Wednesday, July 28, 2021 - 2:47pm

Receiving the AOAC Research Institutes Performance Tested MethodsSM status demonstrates Eurofins Technologies commitment to providing high quality test methods to its food customers who are seeking a faster, easier and more cost-effective method to test for glyphosate in various commodities.

Key Points: 
  • Receiving the AOAC Research Institutes Performance Tested MethodsSM status demonstrates Eurofins Technologies commitment to providing high quality test methods to its food customers who are seeking a faster, easier and more cost-effective method to test for glyphosate in various commodities.
  • The AOAC Research Institute (AOAC RI) is a division of AOAC INTERNATIONAL that promotes and conducts activities to help develop, improve, and validate proprietary testing methods.
  • AOAC INTERNATIONAL is based in Rockville, MD, and is an independent, third-party, nongovernment administrator of the Performance Tested MethodsSM Program.
  • AOAC RI serves diagnostic producers by establishing and maintaining method validation and performance criteria.

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares

Wednesday, July 28, 2021 - 2:34pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced overnight marketed offering (the Offering) of an aggregate of 8,824,000 common shares in the capital of the Company (the Shares) at a price of $3.40 per Share for total gross proceeds of $30,001,600.

Key Points: 
  • Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) (Cybin or the Company), a biotechnology company focused on progressing psychedelic therapeutics, announced today the pricing of its previously announced overnight marketed offering (the Offering) of an aggregate of 8,824,000 common shares in the capital of the Company (the Shares) at a price of $3.40 per Share for total gross proceeds of $30,001,600.
  • The Over-Allotment Option may be exercised in whole or in part as determined by the Underwriters.
  • The Company intends to use the net proceeds from the Offering for general corporate and working capital purposes.
  • has neither approved nor disapproved the contents of this news release and is not responsible for the adequacy and accuracy of the contents herein.

Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market Report 2021-2025: Market is Poised to Grow by $265.55 Million - Increase in Chronic Diseases Driving Market Growth - ResearchAndMarkets.com

Wednesday, July 28, 2021 - 1:49pm

The "Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Enzyme-linked Immunosorbent Assay (Elisa) Testing Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The report on the enzyme-linked immunosorbent assay (Elisa) testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The enzyme-linked immunosorbent assay (Elisa) testing market analysis includes the end-user segment and geographic landscape.
  • This study identifies the increase in chronic diseases as one of the prime reasons driving the enzyme-linked immunosorbent assay (Elisa) testing market growth during the next few years.

Stanley Lapidus, Founder and Former Chairman & CEO of Exact Sciences, Joins PAVmed Subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors

Wednesday, July 28, 2021 - 2:30pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210728005556/en/
    Stanley Lapidus, founder and former Chairman & CEO of Exact Sciences, joins PAVmed subsidiary Lucid Diagnostics as Vice Chairman of its Board of Directors (Photo: Business Wire)
    I am honored to welcome Stan Lapidus to Lucids Board of Directors, said Lishan Aklog, M.D., PAVmeds Chairman and Chief Executive Officer and Lucids Executive Chairman.
  • I look forward to working with him even more closely in his new role as Vice Chairman, as Lucid seeks to execute on its long-term growth strategy.
  • My primary professional quest, over more than three decades, has been to save lives through the early detection of precancer and cancer.
  • For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com , follow Lucid on Twitter , and connect with Lucid on LinkedIn .

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

Wednesday, July 28, 2021 - 1:00pm

National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.

Key Points: 
  • National Resilience, Inc. (Resilience) and bluebird bio, Inc. (NASDAQ: BLUE), today announced a strategic alliance aimed to accelerate the early research, development and delivery of cell therapies.
  • Resilience will continue to support vector supply for both bluebird bio and 2seventy bio, bluebirds spin-off oncology cell therapy company that is expected to launch by the end of 2021.
  • View the full release here: https://www.businesswire.com/news/home/20210728005511/en/
    The 125,000-square foot facility, located in Durham, North Carolina, is currently manufacturing lentiviral vector (LVV), a critical component for cell and gene therapies.
  • In consideration for the acquisition of the bRT facility upon the closing of the transaction, bluebird will receive $110 million from Resilience.